Royalty Pharma (NASDAQ:RPRX – Get Free Report) had its price target lifted by research analysts at TD Cowen from $68.00 to $80.00 in a research note issued on Wednesday, Marketbeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen‘s price target suggests a potential upside of 18.13% from the stock’s previous close.
Several other equities analysts also recently commented on RPRX. Zacks Research raised Royalty Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 11th. The Goldman Sachs Group reissued a “buy” rating and set a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Citigroup lifted their price target on Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Morgan Stanley boosted their price target on Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $65.00.
Check Out Our Latest Report on RPRX
Royalty Pharma Stock Down 1.4%
Insider Buying and Selling
In other news, EVP Marshall Urist sold 4,126 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 232,536 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $68.87, for a total transaction of $16,014,754.32. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 440,788 shares of company stock valued at $29,157,162. 18.84% of the stock is owned by company insiders.
Institutional Investors Weigh In On Royalty Pharma
Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its holdings in Royalty Pharma by 29.0% in the 1st quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock valued at $167,696,000 after acquiring an additional 786,921 shares in the last quarter. Amundi lifted its position in shares of Royalty Pharma by 15.3% during the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock valued at $148,168,000 after acquiring an additional 409,394 shares during the period. Regal Partners Ltd lifted its position in shares of Royalty Pharma by 2.9% during the 3rd quarter. Regal Partners Ltd now owns 2,519,922 shares of the biopharmaceutical company’s stock valued at $147,063,000 after acquiring an additional 72,043 shares during the period. Dorsey Asset Management LLC grew its holdings in shares of Royalty Pharma by 0.8% during the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock worth $109,207,000 after purchasing an additional 17,101 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Royalty Pharma by 5.8% during the 1st quarter. Swiss National Bank now owns 1,191,100 shares of the biopharmaceutical company’s stock worth $57,137,000 after purchasing an additional 65,700 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.
About Royalty Pharma
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Further Reading
- Five stocks we like better than Royalty Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
